Since E2F1 plays an important role in cardiac myocyte growth and is also involved in metabolism regulation through PDK4 modulation, targeting this transcription factor could provide us with an effective therapy for treating detrimental left ventricular hypertrophy leading to heart failure. Here, PDK4 is linked to heart failure.